The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned ...

N4 Pharma Plc (AIM: N4P), the specialist preclinical stage biotech company announces a new lead programme, N4 101. This orally-delivered inflammation inhibitor for Irritable Bowel Disease (IBD) uses ...

The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...

The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...